Talk:Bicuculline

This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Pharmacology Low‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles Low This article has been rated as Low-importance on the project's importance scale. project-independent quality rating in the banner shell. Please resolve this conflict if possible. ??? This article has not yet received a rating on the importance scale. This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Bicuculline. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

As of 3/7/2013, 11:40am EST, the line reads:

"In addition to being a potent GABAA receptor antagonist, bicuculine can be used to block Ca2+-activated potassium channels."

The issue with this statement is that the reference article used to support it actually demonstrates that "methyl" bicuculline, rather than bicuculline itself, has the capacity to block these channels. It may very well be that bicuculline can also block these channels, however the aforementioned reference should be changed or the statement should be removed. — Preceding unsigned comment added by Organiz (talk • contribs) 16:39, 7 March 2013 (UTC)[reply]